Overview:

Summary

Global Markets Direct’s, 'Blepharitis - Pipeline Review, Q2 2011', provides an overview of the Blepharitis therapeutic pipeline. This report provides information on the therapeutic development for Blepharitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Blepharitis. 'Blepharitis - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Blepharitis.
- A review of the Blepharitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Blepharitis pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Blepharitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Blepharitis pipeline depth and focus of Blepharitis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Blepharitis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Blepharitis 7
Blepharitis Therapeutics under Development by Companies 9
Blepharitis Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Blepharitis Therapeutics - Products under Development by Companies 15
Blepharitis Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in Blepharitis Therapeutics Development 17
Lux Biosciences, Inc. 17
Galderma S.A. 17
InSite Vision Incorporated 18
Blepharitis - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Late Stage Drug Profiles 24
AzaSite Plus - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
ISV-305 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Interleukin-1-Receptor Antagonist - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
LX214 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
LX212 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
COL-101 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Blepharitis Therapeutics – Drug Profile Updates 30
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 32
Contact Us 32
Disclaimer 32"

List of Tables
Number of Products Under Development for Blepharitis, Q2 2011 7
Products under Development for Blepharitis – Comparative Analysis, Q2 2011 8
Number of Products under Development by Companies, Q2 2011 9
Number of Products under Investigation by Universities/Institutes, Q2 2011 10
Comparative Analysis by Late Stage Development, Q2 2011 11
Comparative Analysis by Mid Clinical Stage Development, Q2 2011 12
Comparative Analysis by Early Clinical Stage Development, Q2 2011 13
Comparative Analysis by Pre-Clinical Stage Development, Q2 2011 14
Products under Development by Companies, Q2 2011 15
Products under Investigation by Universities/Institutes, Q2 2011 16
Lux Biosciences, Inc., 2011 17
Galderma S.A., 2011 17
InSite Vision Incorporated, 2011 18
Assessment by Monotherapy Products, Q2 2011 19
Assessment by Stage and Route of Administration, Q2 2011 21
Assessment by Molecule Type, Q2 2011 23
Blepharitis Therapeutics – Drug Profile Updates 30"

List of Figures
Number of Products under Development for Blepharitis, Q2 2011 7
Products under Development for Blepharitis – Comparative Analysis, Q2 2011 8
Products under Development by Companies, Q2 2011 9
Products under Investigation by  Universities/Institutes, Q2 2011 10
Late Stage Products, Q2 2011 11
Mid Clinical Stage Products, Q2 2011 12
Early Clinical Stage Products, Q2 2011 13
Pre-Clinical Stage Products, Q2 2011 14
Assessment by Monotherapy Products, Q2 2011 19
Assessment by Route of Administration, Q2 2011 20
Assessment by Stage and Route of Administration, Q2 2011 21
Assessment by Molecule Type, Q2 2011 22
Assessment by Stage and Molecule Type, Q2 2011 23